Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (Maps) Sars Cov-2 Vaccine

Cieslewicz Brian
ORCID logo ,
Daniel Makrinos
,
Heidi Burke
,
Dara Bree
,
Renuka Haridas
,
Ian Tonkiss
,
Yannic Bartsch
,
Galit Alter
,
Richard Malley
,
Gilles Besin
* ORCID logo
Version 1 : Received: 27 May 2022 / Approved: 7 June 2022 / Online: 7 June 2022 (09:00:26 CEST)

A peer-reviewed article of this Preprint also exists.

Cieslewicz, B.; Makrinos, D.; Burke, H.; Bree, D.; Haridas, R.; Tonkiss, I.; Bartsch, Y.; Alter, G.; Malley, R.; Besin, G. Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPSTM) SARS-CoV-2 Vaccine. Vaccines 2022, 10, 1069. Cieslewicz, B.; Makrinos, D.; Burke, H.; Bree, D.; Haridas, R.; Tonkiss, I.; Bartsch, Y.; Alter, G.; Malley, R.; Besin, G. Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPSTM) SARS-CoV-2 Vaccine. Vaccines 2022, 10, 1069.

Abstract

Despite the remarkable success of SARS CoV-2 vaccines, the rise of variants, some of which are more resistant to the effects of vaccination, highlights the potential need for additional COVID-19 vaccines. We used the Multiple Antigen Presenting System (MAPS) technology, in which proteins are presented on a polysaccharide polymer to induce antibody, Th1, Th17 and CD8+ T cell responses, to engineer a novel vaccine targeting SARS CoV-2. This vaccine contains a fragment of the spike (S) protein receptor-binding domain (RBD) sequence of the original D614G strain and was used to immunize nonhuman primates (NHP) for assessment of immunological responses and protection against SARS CoV-2 challenge. The SARS CoV-2 MAPS vaccine generated robust neutralizing antibodies as well as Th1, Th17 and cytotoxic CD8 T-cell responses in NHPs. Furthermore, MAPS-immunized NHPs had significantly lower viral loads in the nasopharynx and lung compared to control animals. Taken together, these findings support the use of the MAPS platform to make a SARS CoV-2 vaccine. The nature of the platform also could enable its use for the inclusion of different variants in a single vaccine.

Keywords

SARS CoV-2 Vaccine; MAPS

Subject

Biology and Life Sciences, Immunology and Microbiology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 1
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.